About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6558 record(s)
Nothing to report this month
Organization: Exinvest Inc.
Req # A-2019-001738
Adverse Drug Reactions (ADRs) for PANTOPRAZOLE SODIUM. Report numbers: E2B_02781670, E2B_02781701, E2B_02785807, E2B_02785829, E2B_02786030, E2B_02786035, E2B_02775045.Organization: Health Canada
January 2025
Req # A-2020-000352
Adverse Drug Reactions (ADRs) for INSULIN GLARGINE. Report numbers: 727720, 000728214, 729829, E2B_02748555, E2B_02755215.Organization: Health Canada
January 2025
Req # A-2020-001377
Adverse Drug Reactions (ADRs). Report numbers: E2B_02850613, E2B_02850821, E2B_02850858, E2B_02850951, E2B_02851375, E2B_02851993, E2B_02852024, E2B_02852029, E2B_02852113, E2B_02852837, E2B_02852897, E2B_02853599, E2B_02854208, E2B_02854279,…Organization: Health Canada
January 2025
Req # A-2020-001378
Adverse Drug Reactions (ADRs). Report numbers: E2B_02862159, E2B_02862257, E2B_02862291, E2B_02862812, E2B_02863394, E2B_02864513, E2B_02864648, E2B_02865118, E2B_02865433, E2B_02865511, E2B_02865512, E2B_02865556, E2B_02865678, E2B_02866678,…Organization: Health Canada
January 2025
Req # A-2020-001637
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_03262131, E2B_03262541, E2B_03238488, E2B_03262564, E2B_03264812, E2B_03265184, E2B_03266801, E2B_03267081, E2B_03267270, E2B_03267898, E2B_03269596, E2B_03269992, E2B_03271101,…Organization: Health Canada
January 2025
Req # A-2020-001668
Adverse Drug Reactions (ADRs). Report numbers: 000921252, 000926298, 03346783, E2B_03356699, E2B_03381172, E2B_03390760, E2B_03395953, E2B_03396613, E2B_03405398, and E2B_03405486.Organization: Health Canada
January 2025
Req # A-2021-000395
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-102144-952, COVID Alert App Advisory Council First Interim Report.Organization: Health Canada
January 2025
Req # A-2021-001016
Adverse Drug Reaction (ADR) for ANTI-THYMOCYTE GLOBULIN (RABBIT). Report number: E2B_03960400.Organization: Health Canada
January 2025
Req # A-2021-001150
Adverse Drug Reaction (ADR) for TERIFLUNOMIDE. Report number: E2B_03954332.Organization: Health Canada
January 2025